Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica

Multiple Sclerosis

Volumn 14, Issue 8, 2008, Pages 1061-1067

  Weinstock Guttman, Bianca ^a,b   Miller, C ^a,b   Yeh, E A ^b   Stosic, M ^b   Umhauer, M ^a,b   Batra, N ^a   Munschauer, F ^a,b   Zivadinov, R ^b   Ramanathan, M ^b,c  

^a JACOBS NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Biomarker; Devic's disease; Monitoring; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NATALIZUMAB; NEUROMYELITIS OPTICA IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; RITUXIMAB;

ACUTE DISEASE; ADULT; ANTIBODY DETECTION; ARTICLE; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFICACY; DRUG MONITORING; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MALE; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; OUTCOME ASSESSMENT; TREATMENT RESPONSE; BLOOD; COHORT ANALYSIS; IMMUNOLOGY; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PLASMAPHERESIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SPINE;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; PLASMAPHERESIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SPINE;

EID: 57349186618     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458508092811     Document Type: Article

References (19)

1. Wingerchuk, DM. Neuromyelitis optica: Current concepts. Front Biosci 2004; 9: 834-840.
2. Wingerchuk, DM, Lennon, VA, Lucchinetti, CF, Pittock, SJ, Weinshenker, BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805-815.
3. Lennon, VA, Wingerchuk, DM, Kryzer, TJ, et al. A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112.
4. Weinshenker, BG, Wingerchuk, DM, Vukusic, S, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59: 566-569.
5. Wingerchuk, DM, Lennon, VA, Pittock, SJ, Lucchinetti, CF, Weinshenker, BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485-1489.
6. Jacob, A, Matiello, M, Wingerchuk, DM, Lucchinetti, CF, Pittock, SJ, Weinshenker, BG. Neuromyelitis optica: Changing concepts. J Neuroimmunol 2007; 187: 126-138.
7. Pittock, SJ, Lennon, VA, Krecke, K, Wingerchuk, DM, Lucchinetti, CF, Weinshenker, BG. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63: 390-396.
8. Pittock, SJ, Weinshenker, BG, Lucchinetti, CF, Wingerchuk, DM, Corboy, JR, Lennon, VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 2006; 63: 964-968.
9. Scott, TF, Kassab, SL, Pittock, SJ. Neuromyelitis optica IgG status in acute partial transverse myelitis. Arch Neurol 2006; 63: 1398-1400.
10. Fukazawa, T, Kikuchi, S, Miyagishi, R, et al. CSF pleocytosis and expansion of spinal lesions in Japanese multiple sclerosis with special reference to the new diagnostic criteria. J Neurol 2005; 252: 824-829.
11. Weinstock-Guttman, B, Ramanathan, M, Lincoff, N, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol 2006; 63: 957-963.
12. Lennon, VA, Kryzer, TJ, Pittock, SJ, Verkman, AS, Hinson, SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473-477.
13. Hinson, SR, Pittock, SJ, Lucchinetti, CF, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 2007; 69: 2221-2231.
14. Faria, AC, Barcellos, KS, Andrade, LE. Longitudinal fluctuation of antibodies to extractable nuclear antigens in systemic lupus erythematosus. J Rheumatol 2005; 32: 1267-1272.
15. Gulko, PS, Reveille, JD, Koopman, WJ, Burgard, SL, Bartolucci, AA, Alarcon, GS. Survival impact of autoantibodies in systemic lupus erythematosus. J Rheumatol 1994; 21: 224-228.
16. Romi, F, Skeie, GO, Aarli, JA, Gilhus, NE. The severity of myasthenia gravis correlates with the serum concentration of titin and ryanodine receptor antibodies. Arch Neurol 2000; 57: 1596-1600.
17. Matsuoka, T, Matsushita, T, Kawano, Y, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007; 130: 1206-1223.
18. Takahashi, T, Fujihara, K, Nakashima, I, et al. Antiaquaporin-4 antibody is involved in the pathogenesis of NMO: A study on antibody titre. Brain 2007; 130: 1235-1243.
19. Fidler, JM, DeJoy, SQ, Gibbons, JJ. Selective immunomodulation by the antineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. J Immunol 1986; 137: 727-732.